Pharma & Healthcare
Global Vaginal Yeast Infections Drug Market Research Report 2026
- Feb 24, 26
- ID: 708324
- Pages: 136
- Figures: 130
- Views: 1
This report delivers a comprehensive overview of the global Vaginal Yeast Infections Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Vaginal Yeast Infections Drug. The Vaginal Yeast Infections Drug market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Vaginal Yeast Infections Drug market comprehensively. Regional market sizes by Type, by Application, by Disease Type, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Vaginal Yeast Infections Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Pfizer
Bayer
Sanofi
Teva Pharmaceuticals
Sandoz
Prestige Consumer Healthcare
Lupin Pharmaceuticals
Bausch Health
Globela Pharma
Padagis
Galderma
Perrigo
Johnson & Johnson
Sinopharm Group
Tongfang Pharmaceutical
Lukang Pharmaceutical
Kelun Pharmaceutical
Shijiazhuang Pharmaceutical Group
Livzon Pharmaceutical
Wuhan Haite Biopharmaceutical
Segment by Type
Topical Drugs
Oral Drugs
Segment by Disease Type
Uncomplicated VVC
Complicated VVC
Other
Segment by Drug Class
Azoles
Polyenes
Novel Oral Antifungals
Other
by Application
Hospital Pharmacies
Retail Pharmacies
Online
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Disease Type, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Vaginal Yeast Infections Drug manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Vaginal Yeast Infections Drug sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Vaginal Yeast Infections Drug market comprehensively. Regional market sizes by Type, by Application, by Disease Type, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Vaginal Yeast Infections Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Pfizer
Bayer
Sanofi
Teva Pharmaceuticals
Sandoz
Prestige Consumer Healthcare
Lupin Pharmaceuticals
Bausch Health
Globela Pharma
Padagis
Galderma
Perrigo
Johnson & Johnson
Sinopharm Group
Tongfang Pharmaceutical
Lukang Pharmaceutical
Kelun Pharmaceutical
Shijiazhuang Pharmaceutical Group
Livzon Pharmaceutical
Wuhan Haite Biopharmaceutical
Segment by Type
Topical Drugs
Oral Drugs
Segment by Disease Type
Uncomplicated VVC
Complicated VVC
Other
Segment by Drug Class
Azoles
Polyenes
Novel Oral Antifungals
Other
by Application
Hospital Pharmacies
Retail Pharmacies
Online
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Disease Type, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Vaginal Yeast Infections Drug manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Vaginal Yeast Infections Drug sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Vaginal Yeast Infections Drug Market Overview
1.1 Product Definition
1.2 Vaginal Yeast Infections Drug by Type
1.2.1 Global Vaginal Yeast Infections Drug Market Value by Type: 2025 vs 2032
1.2.2 Topical Drugs
1.2.3 Oral Drugs
1.3 Vaginal Yeast Infections Drug by Disease Type
1.3.1 Global Vaginal Yeast Infections Drug Market Value by Disease Type: 2025 vs 2032
1.3.2 Uncomplicated VVC
1.3.3 Complicated VVC
1.3.4 Other
1.4 Vaginal Yeast Infections Drug by Drug Class
1.4.1 Global Vaginal Yeast Infections Drug Market Value by Drug Class: 2025 vs 2032
1.4.2 Azoles
1.4.3 Polyenes
1.4.4 Novel Oral Antifungals
1.4.5 Other
1.5 Vaginal Yeast Infections Drug by Application
1.5.1 Global Vaginal Yeast Infections Drug Market Value by Application: 2025 vs 2032
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online
1.6 Global Vaginal Yeast Infections Drug Market Size Estimates and Forecasts
1.6.1 Global Vaginal Yeast Infections Drug Revenue 2021–2032
1.6.2 Global Vaginal Yeast Infections Drug Sales 2021–2032
1.6.3 Global Vaginal Yeast Infections Drug Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Vaginal Yeast Infections Drug Market Competition by Manufacturers
2.1 Global Vaginal Yeast Infections Drug Sales Market Share by Manufacturers (2021–2026)
2.2 Global Vaginal Yeast Infections Drug Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Vaginal Yeast Infections Drug Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Vaginal Yeast Infections Drug, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Vaginal Yeast Infections Drug, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Vaginal Yeast Infections Drug, Product Types and Applications
2.7 Global Key Manufacturers of Vaginal Yeast Infections Drug, Date of Entry into the Industry
2.8 Global Vaginal Yeast Infections Drug Market Competitive Situation and Trends
2.8.1 Global Vaginal Yeast Infections Drug Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Vaginal Yeast Infections Drug Players Market Share by Revenue
2.8.3 Global Vaginal Yeast Infections Drug Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Vaginal Yeast Infections Drug Market Scenario by Region
3.1 Global Vaginal Yeast Infections Drug Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Vaginal Yeast Infections Drug Sales by Region: 2021–2032
3.2.1 Global Vaginal Yeast Infections Drug Sales by Region: 2021–2026
3.2.2 Global Vaginal Yeast Infections Drug Sales by Region: 2027–2032
3.3 Global Vaginal Yeast Infections Drug Revenue by Region: 2021–2032
3.3.1 Global Vaginal Yeast Infections Drug Revenue by Region: 2021–2026
3.3.2 Global Vaginal Yeast Infections Drug Revenue by Region: 2027–2032
3.4 North America Vaginal Yeast Infections Drug Market Facts & Figures by Country
3.4.1 North America Vaginal Yeast Infections Drug Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Vaginal Yeast Infections Drug Sales by Country (2021–2032)
3.4.3 North America Vaginal Yeast Infections Drug Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Vaginal Yeast Infections Drug Market Facts & Figures by Country
3.5.1 Europe Vaginal Yeast Infections Drug Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Vaginal Yeast Infections Drug Sales by Country (2021–2032)
3.5.3 Europe Vaginal Yeast Infections Drug Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Vaginal Yeast Infections Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Vaginal Yeast Infections Drug Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Vaginal Yeast Infections Drug Sales by Region (2021–2032)
3.6.3 Asia Pacific Vaginal Yeast Infections Drug Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Vaginal Yeast Infections Drug Market Facts & Figures by Country
3.7.1 Latin America Vaginal Yeast Infections Drug Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Vaginal Yeast Infections Drug Sales by Country (2021–2032)
3.7.3 Latin America Vaginal Yeast Infections Drug Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Vaginal Yeast Infections Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Vaginal Yeast Infections Drug Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Vaginal Yeast Infections Drug Sales by Country (2021–2032)
3.8.3 Middle East and Africa Vaginal Yeast Infections Drug Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Vaginal Yeast Infections Drug Sales by Type (2021–2032)
4.1.1 Global Vaginal Yeast Infections Drug Sales by Type (2021–2026)
4.1.2 Global Vaginal Yeast Infections Drug Sales by Type (2027–2032)
4.1.3 Global Vaginal Yeast Infections Drug Sales Market Share by Type (2021–2032)
4.2 Global Vaginal Yeast Infections Drug Revenue by Type (2021–2032)
4.2.1 Global Vaginal Yeast Infections Drug Revenue by Type (2021–2026)
4.2.2 Global Vaginal Yeast Infections Drug Revenue by Type (2027–2032)
4.2.3 Global Vaginal Yeast Infections Drug Revenue Market Share by Type (2021–2032)
4.3 Global Vaginal Yeast Infections Drug Price by Type (2021–2032)
5 Segment by Application
5.1 Global Vaginal Yeast Infections Drug Sales by Application (2021–2032)
5.1.1 Global Vaginal Yeast Infections Drug Sales by Application (2021–2026)
5.1.2 Global Vaginal Yeast Infections Drug Sales by Application (2027–2032)
5.1.3 Global Vaginal Yeast Infections Drug Sales Market Share by Application (2021–2032)
5.2 Global Vaginal Yeast Infections Drug Revenue by Application (2021–2032)
5.2.1 Global Vaginal Yeast Infections Drug Revenue by Application (2021–2026)
5.2.2 Global Vaginal Yeast Infections Drug Revenue by Application (2027–2032)
5.2.3 Global Vaginal Yeast Infections Drug Revenue Market Share by Application (2021–2032)
5.3 Global Vaginal Yeast Infections Drug Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Pfizer Vaginal Yeast Infections Drug Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Company Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Bayer Vaginal Yeast Infections Drug Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Sanofi Vaginal Yeast Infections Drug Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Teva Pharmaceuticals
6.4.1 Teva Pharmaceuticals Company Information
6.4.2 Teva Pharmaceuticals Description and Business Overview
6.4.3 Teva Pharmaceuticals Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Teva Pharmaceuticals Vaginal Yeast Infections Drug Product Portfolio
6.4.5 Teva Pharmaceuticals Recent Developments/Updates
6.5 Sandoz
6.5.1 Sandoz Company Information
6.5.2 Sandoz Description and Business Overview
6.5.3 Sandoz Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Sandoz Vaginal Yeast Infections Drug Product Portfolio
6.5.5 Sandoz Recent Developments/Updates
6.6 Prestige Consumer Healthcare
6.6.1 Prestige Consumer Healthcare Company Information
6.6.2 Prestige Consumer Healthcare Description and Business Overview
6.6.3 Prestige Consumer Healthcare Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Prestige Consumer Healthcare Vaginal Yeast Infections Drug Product Portfolio
6.6.5 Prestige Consumer Healthcare Recent Developments/Updates
6.7 Lupin Pharmaceuticals
6.7.1 Lupin Pharmaceuticals Company Information
6.7.2 Lupin Pharmaceuticals Description and Business Overview
6.7.3 Lupin Pharmaceuticals Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Lupin Pharmaceuticals Vaginal Yeast Infections Drug Product Portfolio
6.7.5 Lupin Pharmaceuticals Recent Developments/Updates
6.8 Bausch Health
6.8.1 Bausch Health Company Information
6.8.2 Bausch Health Description and Business Overview
6.8.3 Bausch Health Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Bausch Health Vaginal Yeast Infections Drug Product Portfolio
6.8.5 Bausch Health Recent Developments/Updates
6.9 Globela Pharma
6.9.1 Globela Pharma Company Information
6.9.2 Globela Pharma Description and Business Overview
6.9.3 Globela Pharma Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Globela Pharma Vaginal Yeast Infections Drug Product Portfolio
6.9.5 Globela Pharma Recent Developments/Updates
6.10 Padagis
6.10.1 Padagis Company Information
6.10.2 Padagis Description and Business Overview
6.10.3 Padagis Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Padagis Vaginal Yeast Infections Drug Product Portfolio
6.10.5 Padagis Recent Developments/Updates
6.11 Galderma
6.11.1 Galderma Company Information
6.11.2 Galderma Description and Business Overview
6.11.3 Galderma Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Galderma Vaginal Yeast Infections Drug Product Portfolio
6.11.5 Galderma Recent Developments/Updates
6.12 Perrigo
6.12.1 Perrigo Company Information
6.12.2 Perrigo Description and Business Overview
6.12.3 Perrigo Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Perrigo Vaginal Yeast Infections Drug Product Portfolio
6.12.5 Perrigo Recent Developments/Updates
6.13 Johnson & Johnson
6.13.1 Johnson & Johnson Company Information
6.13.2 Johnson & Johnson Description and Business Overview
6.13.3 Johnson & Johnson Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Johnson & Johnson Vaginal Yeast Infections Drug Product Portfolio
6.13.5 Johnson & Johnson Recent Developments/Updates
6.14 Sinopharm Group
6.14.1 Sinopharm Group Company Information
6.14.2 Sinopharm Group Description and Business Overview
6.14.3 Sinopharm Group Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Sinopharm Group Vaginal Yeast Infections Drug Product Portfolio
6.14.5 Sinopharm Group Recent Developments/Updates
6.15 Tongfang Pharmaceutical
6.15.1 Tongfang Pharmaceutical Company Information
6.15.2 Tongfang Pharmaceutical Description and Business Overview
6.15.3 Tongfang Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Tongfang Pharmaceutical Vaginal Yeast Infections Drug Product Portfolio
6.15.5 Tongfang Pharmaceutical Recent Developments/Updates
6.16 Lukang Pharmaceutical
6.16.1 Lukang Pharmaceutical Company Information
6.16.2 Lukang Pharmaceutical Description and Business Overview
6.16.3 Lukang Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Lukang Pharmaceutical Vaginal Yeast Infections Drug Product Portfolio
6.16.5 Lukang Pharmaceutical Recent Developments/Updates
6.17 Kelun Pharmaceutical
6.17.1 Kelun Pharmaceutical Company Information
6.17.2 Kelun Pharmaceutical Description and Business Overview
6.17.3 Kelun Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Kelun Pharmaceutical Vaginal Yeast Infections Drug Product Portfolio
6.17.5 Kelun Pharmaceutical Recent Developments/Updates
6.18 Shijiazhuang Pharmaceutical Group
6.18.1 Shijiazhuang Pharmaceutical Group Company Information
6.18.2 Shijiazhuang Pharmaceutical Group Description and Business Overview
6.18.3 Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Product Portfolio
6.18.5 Shijiazhuang Pharmaceutical Group Recent Developments/Updates
6.19 Livzon Pharmaceutical
6.19.1 Livzon Pharmaceutical Company Information
6.19.2 Livzon Pharmaceutical Description and Business Overview
6.19.3 Livzon Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Livzon Pharmaceutical Vaginal Yeast Infections Drug Product Portfolio
6.19.5 Livzon Pharmaceutical Recent Developments/Updates
6.20 Wuhan Haite Biopharmaceutical
6.20.1 Wuhan Haite Biopharmaceutical Company Information
6.20.2 Wuhan Haite Biopharmaceutical Description and Business Overview
6.20.3 Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.20.4 Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Product Portfolio
6.20.5 Wuhan Haite Biopharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Vaginal Yeast Infections Drug Industry Chain Analysis
7.2 Vaginal Yeast Infections Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Vaginal Yeast Infections Drug Production Mode & Process Analysis
7.4 Vaginal Yeast Infections Drug Sales and Marketing
7.4.1 Vaginal Yeast Infections Drug Sales Channels
7.4.2 Vaginal Yeast Infections Drug Distributors
7.5 Vaginal Yeast Infections Drug Customer Analysis
8 Vaginal Yeast Infections Drug Market Dynamics
8.1 Vaginal Yeast Infections Drug Industry Trends
8.2 Vaginal Yeast Infections Drug Market Drivers
8.3 Vaginal Yeast Infections Drug Market Challenges
8.4 Vaginal Yeast Infections Drug Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Vaginal Yeast Infections Drug by Type
1.2.1 Global Vaginal Yeast Infections Drug Market Value by Type: 2025 vs 2032
1.2.2 Topical Drugs
1.2.3 Oral Drugs
1.3 Vaginal Yeast Infections Drug by Disease Type
1.3.1 Global Vaginal Yeast Infections Drug Market Value by Disease Type: 2025 vs 2032
1.3.2 Uncomplicated VVC
1.3.3 Complicated VVC
1.3.4 Other
1.4 Vaginal Yeast Infections Drug by Drug Class
1.4.1 Global Vaginal Yeast Infections Drug Market Value by Drug Class: 2025 vs 2032
1.4.2 Azoles
1.4.3 Polyenes
1.4.4 Novel Oral Antifungals
1.4.5 Other
1.5 Vaginal Yeast Infections Drug by Application
1.5.1 Global Vaginal Yeast Infections Drug Market Value by Application: 2025 vs 2032
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online
1.6 Global Vaginal Yeast Infections Drug Market Size Estimates and Forecasts
1.6.1 Global Vaginal Yeast Infections Drug Revenue 2021–2032
1.6.2 Global Vaginal Yeast Infections Drug Sales 2021–2032
1.6.3 Global Vaginal Yeast Infections Drug Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Vaginal Yeast Infections Drug Market Competition by Manufacturers
2.1 Global Vaginal Yeast Infections Drug Sales Market Share by Manufacturers (2021–2026)
2.2 Global Vaginal Yeast Infections Drug Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Vaginal Yeast Infections Drug Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Vaginal Yeast Infections Drug, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Vaginal Yeast Infections Drug, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Vaginal Yeast Infections Drug, Product Types and Applications
2.7 Global Key Manufacturers of Vaginal Yeast Infections Drug, Date of Entry into the Industry
2.8 Global Vaginal Yeast Infections Drug Market Competitive Situation and Trends
2.8.1 Global Vaginal Yeast Infections Drug Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Vaginal Yeast Infections Drug Players Market Share by Revenue
2.8.3 Global Vaginal Yeast Infections Drug Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Vaginal Yeast Infections Drug Market Scenario by Region
3.1 Global Vaginal Yeast Infections Drug Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Vaginal Yeast Infections Drug Sales by Region: 2021–2032
3.2.1 Global Vaginal Yeast Infections Drug Sales by Region: 2021–2026
3.2.2 Global Vaginal Yeast Infections Drug Sales by Region: 2027–2032
3.3 Global Vaginal Yeast Infections Drug Revenue by Region: 2021–2032
3.3.1 Global Vaginal Yeast Infections Drug Revenue by Region: 2021–2026
3.3.2 Global Vaginal Yeast Infections Drug Revenue by Region: 2027–2032
3.4 North America Vaginal Yeast Infections Drug Market Facts & Figures by Country
3.4.1 North America Vaginal Yeast Infections Drug Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Vaginal Yeast Infections Drug Sales by Country (2021–2032)
3.4.3 North America Vaginal Yeast Infections Drug Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Vaginal Yeast Infections Drug Market Facts & Figures by Country
3.5.1 Europe Vaginal Yeast Infections Drug Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Vaginal Yeast Infections Drug Sales by Country (2021–2032)
3.5.3 Europe Vaginal Yeast Infections Drug Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Vaginal Yeast Infections Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Vaginal Yeast Infections Drug Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Vaginal Yeast Infections Drug Sales by Region (2021–2032)
3.6.3 Asia Pacific Vaginal Yeast Infections Drug Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Vaginal Yeast Infections Drug Market Facts & Figures by Country
3.7.1 Latin America Vaginal Yeast Infections Drug Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Vaginal Yeast Infections Drug Sales by Country (2021–2032)
3.7.3 Latin America Vaginal Yeast Infections Drug Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Vaginal Yeast Infections Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Vaginal Yeast Infections Drug Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Vaginal Yeast Infections Drug Sales by Country (2021–2032)
3.8.3 Middle East and Africa Vaginal Yeast Infections Drug Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Vaginal Yeast Infections Drug Sales by Type (2021–2032)
4.1.1 Global Vaginal Yeast Infections Drug Sales by Type (2021–2026)
4.1.2 Global Vaginal Yeast Infections Drug Sales by Type (2027–2032)
4.1.3 Global Vaginal Yeast Infections Drug Sales Market Share by Type (2021–2032)
4.2 Global Vaginal Yeast Infections Drug Revenue by Type (2021–2032)
4.2.1 Global Vaginal Yeast Infections Drug Revenue by Type (2021–2026)
4.2.2 Global Vaginal Yeast Infections Drug Revenue by Type (2027–2032)
4.2.3 Global Vaginal Yeast Infections Drug Revenue Market Share by Type (2021–2032)
4.3 Global Vaginal Yeast Infections Drug Price by Type (2021–2032)
5 Segment by Application
5.1 Global Vaginal Yeast Infections Drug Sales by Application (2021–2032)
5.1.1 Global Vaginal Yeast Infections Drug Sales by Application (2021–2026)
5.1.2 Global Vaginal Yeast Infections Drug Sales by Application (2027–2032)
5.1.3 Global Vaginal Yeast Infections Drug Sales Market Share by Application (2021–2032)
5.2 Global Vaginal Yeast Infections Drug Revenue by Application (2021–2032)
5.2.1 Global Vaginal Yeast Infections Drug Revenue by Application (2021–2026)
5.2.2 Global Vaginal Yeast Infections Drug Revenue by Application (2027–2032)
5.2.3 Global Vaginal Yeast Infections Drug Revenue Market Share by Application (2021–2032)
5.3 Global Vaginal Yeast Infections Drug Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Pfizer Vaginal Yeast Infections Drug Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Company Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Bayer Vaginal Yeast Infections Drug Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Sanofi Vaginal Yeast Infections Drug Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Teva Pharmaceuticals
6.4.1 Teva Pharmaceuticals Company Information
6.4.2 Teva Pharmaceuticals Description and Business Overview
6.4.3 Teva Pharmaceuticals Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Teva Pharmaceuticals Vaginal Yeast Infections Drug Product Portfolio
6.4.5 Teva Pharmaceuticals Recent Developments/Updates
6.5 Sandoz
6.5.1 Sandoz Company Information
6.5.2 Sandoz Description and Business Overview
6.5.3 Sandoz Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Sandoz Vaginal Yeast Infections Drug Product Portfolio
6.5.5 Sandoz Recent Developments/Updates
6.6 Prestige Consumer Healthcare
6.6.1 Prestige Consumer Healthcare Company Information
6.6.2 Prestige Consumer Healthcare Description and Business Overview
6.6.3 Prestige Consumer Healthcare Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Prestige Consumer Healthcare Vaginal Yeast Infections Drug Product Portfolio
6.6.5 Prestige Consumer Healthcare Recent Developments/Updates
6.7 Lupin Pharmaceuticals
6.7.1 Lupin Pharmaceuticals Company Information
6.7.2 Lupin Pharmaceuticals Description and Business Overview
6.7.3 Lupin Pharmaceuticals Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Lupin Pharmaceuticals Vaginal Yeast Infections Drug Product Portfolio
6.7.5 Lupin Pharmaceuticals Recent Developments/Updates
6.8 Bausch Health
6.8.1 Bausch Health Company Information
6.8.2 Bausch Health Description and Business Overview
6.8.3 Bausch Health Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Bausch Health Vaginal Yeast Infections Drug Product Portfolio
6.8.5 Bausch Health Recent Developments/Updates
6.9 Globela Pharma
6.9.1 Globela Pharma Company Information
6.9.2 Globela Pharma Description and Business Overview
6.9.3 Globela Pharma Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Globela Pharma Vaginal Yeast Infections Drug Product Portfolio
6.9.5 Globela Pharma Recent Developments/Updates
6.10 Padagis
6.10.1 Padagis Company Information
6.10.2 Padagis Description and Business Overview
6.10.3 Padagis Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Padagis Vaginal Yeast Infections Drug Product Portfolio
6.10.5 Padagis Recent Developments/Updates
6.11 Galderma
6.11.1 Galderma Company Information
6.11.2 Galderma Description and Business Overview
6.11.3 Galderma Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Galderma Vaginal Yeast Infections Drug Product Portfolio
6.11.5 Galderma Recent Developments/Updates
6.12 Perrigo
6.12.1 Perrigo Company Information
6.12.2 Perrigo Description and Business Overview
6.12.3 Perrigo Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Perrigo Vaginal Yeast Infections Drug Product Portfolio
6.12.5 Perrigo Recent Developments/Updates
6.13 Johnson & Johnson
6.13.1 Johnson & Johnson Company Information
6.13.2 Johnson & Johnson Description and Business Overview
6.13.3 Johnson & Johnson Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Johnson & Johnson Vaginal Yeast Infections Drug Product Portfolio
6.13.5 Johnson & Johnson Recent Developments/Updates
6.14 Sinopharm Group
6.14.1 Sinopharm Group Company Information
6.14.2 Sinopharm Group Description and Business Overview
6.14.3 Sinopharm Group Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Sinopharm Group Vaginal Yeast Infections Drug Product Portfolio
6.14.5 Sinopharm Group Recent Developments/Updates
6.15 Tongfang Pharmaceutical
6.15.1 Tongfang Pharmaceutical Company Information
6.15.2 Tongfang Pharmaceutical Description and Business Overview
6.15.3 Tongfang Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Tongfang Pharmaceutical Vaginal Yeast Infections Drug Product Portfolio
6.15.5 Tongfang Pharmaceutical Recent Developments/Updates
6.16 Lukang Pharmaceutical
6.16.1 Lukang Pharmaceutical Company Information
6.16.2 Lukang Pharmaceutical Description and Business Overview
6.16.3 Lukang Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Lukang Pharmaceutical Vaginal Yeast Infections Drug Product Portfolio
6.16.5 Lukang Pharmaceutical Recent Developments/Updates
6.17 Kelun Pharmaceutical
6.17.1 Kelun Pharmaceutical Company Information
6.17.2 Kelun Pharmaceutical Description and Business Overview
6.17.3 Kelun Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Kelun Pharmaceutical Vaginal Yeast Infections Drug Product Portfolio
6.17.5 Kelun Pharmaceutical Recent Developments/Updates
6.18 Shijiazhuang Pharmaceutical Group
6.18.1 Shijiazhuang Pharmaceutical Group Company Information
6.18.2 Shijiazhuang Pharmaceutical Group Description and Business Overview
6.18.3 Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Product Portfolio
6.18.5 Shijiazhuang Pharmaceutical Group Recent Developments/Updates
6.19 Livzon Pharmaceutical
6.19.1 Livzon Pharmaceutical Company Information
6.19.2 Livzon Pharmaceutical Description and Business Overview
6.19.3 Livzon Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Livzon Pharmaceutical Vaginal Yeast Infections Drug Product Portfolio
6.19.5 Livzon Pharmaceutical Recent Developments/Updates
6.20 Wuhan Haite Biopharmaceutical
6.20.1 Wuhan Haite Biopharmaceutical Company Information
6.20.2 Wuhan Haite Biopharmaceutical Description and Business Overview
6.20.3 Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, and Gross Margin (2021–2026)
6.20.4 Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Product Portfolio
6.20.5 Wuhan Haite Biopharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Vaginal Yeast Infections Drug Industry Chain Analysis
7.2 Vaginal Yeast Infections Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Vaginal Yeast Infections Drug Production Mode & Process Analysis
7.4 Vaginal Yeast Infections Drug Sales and Marketing
7.4.1 Vaginal Yeast Infections Drug Sales Channels
7.4.2 Vaginal Yeast Infections Drug Distributors
7.5 Vaginal Yeast Infections Drug Customer Analysis
8 Vaginal Yeast Infections Drug Market Dynamics
8.1 Vaginal Yeast Infections Drug Industry Trends
8.2 Vaginal Yeast Infections Drug Market Drivers
8.3 Vaginal Yeast Infections Drug Market Challenges
8.4 Vaginal Yeast Infections Drug Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Vaginal Yeast Infections Drug Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Vaginal Yeast Infections Drug Market Value by Disease Type (US$ Million), 2025 vs 2032
Table 3. Global Vaginal Yeast Infections Drug Market Value by Drug Class (US$ Million), 2025 vs 2032
Table 4. Global Vaginal Yeast Infections Drug Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global Vaginal Yeast Infections Drug Market Competitive Situation by Manufacturers in 2025
Table 6. Global Vaginal Yeast Infections Drug Sales (K Units) of Key Manufacturers (2021–2026)
Table 7. Global Vaginal Yeast Infections Drug Sales Market Share by Manufacturers (2021–2026)
Table 8. Global Vaginal Yeast Infections Drug Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global Vaginal Yeast Infections Drug Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market Vaginal Yeast Infections Drug Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of Vaginal Yeast Infections Drug, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of Vaginal Yeast Infections Drug, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of Vaginal Yeast Infections Drug, Product Types and Applications
Table 14. Global Key Manufacturers of Vaginal Yeast Infections Drug, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Vaginal Yeast Infections Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on Vaginal Yeast Infections Drug Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Vaginal Yeast Infections Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global Vaginal Yeast Infections Drug Sales by Region (K Units), 2021–2026
Table 20. Global Vaginal Yeast Infections Drug Sales Market Share by Region (2021–2026)
Table 21. Global Vaginal Yeast Infections Drug Sales by Region (K Units), 2027–2032
Table 22. Global Vaginal Yeast Infections Drug Sales Market Share by Region (2027–2032)
Table 23. Global Vaginal Yeast Infections Drug Revenue by Region (US$ Million), 2021–2026
Table 24. Global Vaginal Yeast Infections Drug Revenue Market Share by Region (2021–2026)
Table 25. Global Vaginal Yeast Infections Drug Revenue by Region (US$ Million), 2027–2032
Table 26. Global Vaginal Yeast Infections Drug Revenue Market Share by Region (2027–2032)
Table 27. North America Vaginal Yeast Infections Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America Vaginal Yeast Infections Drug Sales by Country (K Units), 2021–2026
Table 29. North America Vaginal Yeast Infections Drug Sales by Country (K Units), 2027–2032
Table 30. North America Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2021–2026
Table 31. North America Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2027–2032
Table 32. Europe Vaginal Yeast Infections Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe Vaginal Yeast Infections Drug Sales by Country (K Units), 2021–2026
Table 34. Europe Vaginal Yeast Infections Drug Sales by Country (K Units), 2027–2032
Table 35. Europe Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2021–2026
Table 36. Europe Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific Vaginal Yeast Infections Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific Vaginal Yeast Infections Drug Sales by Region (K Units), 2021–2026
Table 39. Asia Pacific Vaginal Yeast Infections Drug Sales by Region (K Units), 2027–2032
Table 40. Asia Pacific Vaginal Yeast Infections Drug Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific Vaginal Yeast Infections Drug Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America Vaginal Yeast Infections Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America Vaginal Yeast Infections Drug Sales by Country (K Units), 2021–2026
Table 44. Latin America Vaginal Yeast Infections Drug Sales by Country (K Units), 2027–2032
Table 45. Latin America Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa Vaginal Yeast Infections Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa Vaginal Yeast Infections Drug Sales by Country (K Units), 2021–2026
Table 49. Middle East and Africa Vaginal Yeast Infections Drug Sales by Country (K Units), 2027–2032
Table 50. Middle East and Africa Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2027–2032
Table 52. Global Vaginal Yeast Infections Drug Sales (K Units) by Type (2021–2026)
Table 53. Global Vaginal Yeast Infections Drug Sales (K Units) by Type (2027–2032)
Table 54. Global Vaginal Yeast Infections Drug Sales Market Share by Type (2021–2026)
Table 55. Global Vaginal Yeast Infections Drug Sales Market Share by Type (2027–2032)
Table 56. Global Vaginal Yeast Infections Drug Revenue (US$ Million) by Type (2021–2026)
Table 57. Global Vaginal Yeast Infections Drug Revenue (US$ Million) by Type (2027–2032)
Table 58. Global Vaginal Yeast Infections Drug Revenue Market Share by Type (2021–2026)
Table 59. Global Vaginal Yeast Infections Drug Revenue Market Share by Type (2027–2032)
Table 60. Global Vaginal Yeast Infections Drug Price (US$/Unit) by Type (2021–2026)
Table 61. Global Vaginal Yeast Infections Drug Price (US$/Unit) by Type (2027–2032)
Table 62. Global Vaginal Yeast Infections Drug Sales (K Units) by Application (2021–2026)
Table 63. Global Vaginal Yeast Infections Drug Sales (K Units) by Application (2027–2032)
Table 64. Global Vaginal Yeast Infections Drug Sales Market Share by Application (2021–2026)
Table 65. Global Vaginal Yeast Infections Drug Sales Market Share by Application (2027–2032)
Table 66. Global Vaginal Yeast Infections Drug Revenue (US$ Million) by Application (2021–2026)
Table 67. Global Vaginal Yeast Infections Drug Revenue (US$ Million) by Application (2027–2032)
Table 68. Global Vaginal Yeast Infections Drug Revenue Market Share by Application (2021–2026)
Table 69. Global Vaginal Yeast Infections Drug Revenue Market Share by Application (2027–2032)
Table 70. Global Vaginal Yeast Infections Drug Price (US$/Unit) by Application (2021–2026)
Table 71. Global Vaginal Yeast Infections Drug Price (US$/Unit) by Application (2027–2032)
Table 72. Pfizer Company Information
Table 73. Pfizer Description and Business Overview
Table 74. Pfizer Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 75. Pfizer Vaginal Yeast Infections Drug Product
Table 76. Pfizer Recent Developments/Updates
Table 77. Bayer Company Information
Table 78. Bayer Description and Business Overview
Table 79. Bayer Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 80. Bayer Vaginal Yeast Infections Drug Product
Table 81. Bayer Recent Developments/Updates
Table 82. Sanofi Company Information
Table 83. Sanofi Description and Business Overview
Table 84. Sanofi Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 85. Sanofi Vaginal Yeast Infections Drug Product
Table 86. Sanofi Recent Developments/Updates
Table 87. Teva Pharmaceuticals Company Information
Table 88. Teva Pharmaceuticals Description and Business Overview
Table 89. Teva Pharmaceuticals Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 90. Teva Pharmaceuticals Vaginal Yeast Infections Drug Product
Table 91. Teva Pharmaceuticals Recent Developments/Updates
Table 92. Sandoz Company Information
Table 93. Sandoz Description and Business Overview
Table 94. Sandoz Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 95. Sandoz Vaginal Yeast Infections Drug Product
Table 96. Sandoz Recent Developments/Updates
Table 97. Prestige Consumer Healthcare Company Information
Table 98. Prestige Consumer Healthcare Description and Business Overview
Table 99. Prestige Consumer Healthcare Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 100. Prestige Consumer Healthcare Vaginal Yeast Infections Drug Product
Table 101. Prestige Consumer Healthcare Recent Developments/Updates
Table 102. Lupin Pharmaceuticals Company Information
Table 103. Lupin Pharmaceuticals Description and Business Overview
Table 104. Lupin Pharmaceuticals Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 105. Lupin Pharmaceuticals Vaginal Yeast Infections Drug Product
Table 106. Lupin Pharmaceuticals Recent Developments/Updates
Table 107. Bausch Health Company Information
Table 108. Bausch Health Description and Business Overview
Table 109. Bausch Health Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 110. Bausch Health Vaginal Yeast Infections Drug Product
Table 111. Bausch Health Recent Developments/Updates
Table 112. Globela Pharma Company Information
Table 113. Globela Pharma Description and Business Overview
Table 114. Globela Pharma Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 115. Globela Pharma Vaginal Yeast Infections Drug Product
Table 116. Globela Pharma Recent Developments/Updates
Table 117. Padagis Company Information
Table 118. Padagis Description and Business Overview
Table 119. Padagis Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 120. Padagis Vaginal Yeast Infections Drug Product
Table 121. Padagis Recent Developments/Updates
Table 122. Galderma Company Information
Table 123. Galderma Description and Business Overview
Table 124. Galderma Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 125. Galderma Vaginal Yeast Infections Drug Product
Table 126. Galderma Recent Developments/Updates
Table 127. Perrigo Company Information
Table 128. Perrigo Description and Business Overview
Table 129. Perrigo Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 130. Perrigo Vaginal Yeast Infections Drug Product
Table 131. Perrigo Recent Developments/Updates
Table 132. Johnson & Johnson Company Information
Table 133. Johnson & Johnson Description and Business Overview
Table 134. Johnson & Johnson Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 135. Johnson & Johnson Vaginal Yeast Infections Drug Product
Table 136. Johnson & Johnson Recent Developments/Updates
Table 137. Sinopharm Group Company Information
Table 138. Sinopharm Group Description and Business Overview
Table 139. Sinopharm Group Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 140. Sinopharm Group Vaginal Yeast Infections Drug Product
Table 141. Sinopharm Group Recent Developments/Updates
Table 142. Tongfang Pharmaceutical Company Information
Table 143. Tongfang Pharmaceutical Description and Business Overview
Table 144. Tongfang Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 145. Tongfang Pharmaceutical Vaginal Yeast Infections Drug Product
Table 146. Tongfang Pharmaceutical Recent Developments/Updates
Table 147. Lukang Pharmaceutical Company Information
Table 148. Lukang Pharmaceutical Description and Business Overview
Table 149. Lukang Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 150. Lukang Pharmaceutical Vaginal Yeast Infections Drug Product
Table 151. Lukang Pharmaceutical Recent Developments/Updates
Table 152. Kelun Pharmaceutical Company Information
Table 153. Kelun Pharmaceutical Description and Business Overview
Table 154. Kelun Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 155. Kelun Pharmaceutical Vaginal Yeast Infections Drug Product
Table 156. Kelun Pharmaceutical Recent Developments/Updates
Table 157. Shijiazhuang Pharmaceutical Group Company Information
Table 158. Shijiazhuang Pharmaceutical Group Description and Business Overview
Table 159. Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 160. Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Product
Table 161. Shijiazhuang Pharmaceutical Group Recent Developments/Updates
Table 162. Livzon Pharmaceutical Company Information
Table 163. Livzon Pharmaceutical Description and Business Overview
Table 164. Livzon Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 165. Livzon Pharmaceutical Vaginal Yeast Infections Drug Product
Table 166. Livzon Pharmaceutical Recent Developments/Updates
Table 167. Wuhan Haite Biopharmaceutical Company Information
Table 168. Wuhan Haite Biopharmaceutical Description and Business Overview
Table 169. Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 170. Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Product
Table 171. Wuhan Haite Biopharmaceutical Recent Developments/Updates
Table 172. Key Raw Materials Lists
Table 173. Raw Materials Key Suppliers Lists
Table 174. Vaginal Yeast Infections Drug Distributors List
Table 175. Vaginal Yeast Infections Drug Customers List
Table 176. Vaginal Yeast Infections Drug Market Trends
Table 177. Vaginal Yeast Infections Drug Market Drivers
Table 178. Vaginal Yeast Infections Drug Market Challenges
Table 179. Vaginal Yeast Infections Drug Market Restraints
Table 180. Research Programs/Design for This Report
Table 181. Key Data Information from Secondary Sources
Table 182. Key Data Information from Primary Sources
Table 183. Authors List of This Report
List of Figures
Figure 1. Product Picture of Vaginal Yeast Infections Drug
Figure 2. Global Vaginal Yeast Infections Drug Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Vaginal Yeast Infections Drug Market Share by Type: 2025 & 2032
Figure 4. Topical Drugs Product Picture
Figure 5. Oral Drugs Product Picture
Figure 6. Global Vaginal Yeast Infections Drug Market Value by Disease Type (US$ Million), 2021–2032
Figure 7. Global Vaginal Yeast Infections Drug Market Share by Disease Type: 2025 vs 2032
Figure 8. Uncomplicated VVC Product Picture
Figure 9. Complicated VVC Product Picture
Figure 10. Other Product Picture
Figure 11. Global Vaginal Yeast Infections Drug Market Value by Drug Class (US$ Million), 2021–2032
Figure 12. Global Vaginal Yeast Infections Drug Market Share by Drug Class: 2025 vs 2032
Figure 13. Azoles Product Picture
Figure 14. Polyenes Product Picture
Figure 15. Novel Oral Antifungals Product Picture
Figure 16. Other Product Picture
Figure 17. Global Vaginal Yeast Infections Drug Market Value by Application (US$ Million), 2021–2032
Figure 18. Global Vaginal Yeast Infections Drug Market Share by Application: 2025 & 2032
Figure 19. Hospital Pharmacies
Figure 20. Retail Pharmacies
Figure 21. Online
Figure 22. Global Vaginal Yeast Infections Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 23. Global Vaginal Yeast Infections Drug Market Size (US$ Million), 2021–2032
Figure 24. Global Vaginal Yeast Infections Drug Sales (K Units), 2021–2032
Figure 25. Global Vaginal Yeast Infections Drug Average Price (US$/Unit), 2021–2032
Figure 26. Vaginal Yeast Infections Drug Report Years Considered
Figure 27. Vaginal Yeast Infections Drug Sales Share by Manufacturers in 2025
Figure 28. Global Vaginal Yeast Infections Drug Revenue Share by Manufacturers in 2025
Figure 29. Top 5 and Top 10 Global Vaginal Yeast Infections Drug Players: Market Share by Revenue in Vaginal Yeast Infections Drug in 2025
Figure 30. Vaginal Yeast Infections Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 31. Global Vaginal Yeast Infections Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 32. North America Vaginal Yeast Infections Drug Sales Market Share by Country (2021–2032)
Figure 33. North America Vaginal Yeast Infections Drug Revenue Market Share by Country (2021–2032)
Figure 34. United States Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Canada Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Europe Vaginal Yeast Infections Drug Sales Market Share by Country (2021–2032)
Figure 37. Europe Vaginal Yeast Infections Drug Revenue Market Share by Country (2021–2032)
Figure 38. Germany Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. France Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. U.K. Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Italy Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Russia Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Asia Pacific Vaginal Yeast Infections Drug Sales Market Share by Region (2021–2032)
Figure 44. Asia Pacific Vaginal Yeast Infections Drug Revenue Market Share by Region (2021–2032)
Figure 45. China Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Japan Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. South Korea Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. India Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Australia Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. China Taiwan Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Southeast Asia Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Latin America Vaginal Yeast Infections Drug Sales Market Share by Country (2021–2032)
Figure 53. Latin America Vaginal Yeast Infections Drug Revenue Market Share by Country (2021–2032)
Figure 54. Mexico Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Brazil Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Argentina Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Colombia Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Middle East and Africa Vaginal Yeast Infections Drug Sales Market Share by Country (2021–2032)
Figure 59. Middle East and Africa Vaginal Yeast Infections Drug Revenue Market Share by Country (2021–2032)
Figure 60. Turkey Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. Saudi Arabia Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 62. UAE Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 63. Global Sales Market Share of Vaginal Yeast Infections Drug by Type (2021–2032)
Figure 64. Global Revenue Market Share of Vaginal Yeast Infections Drug by Type (2021–2032)
Figure 65. Global Vaginal Yeast Infections Drug Price (US$/Unit) by Type (2021–2032)
Figure 66. Global Sales Market Share of Vaginal Yeast Infections Drug by Application (2021–2032)
Figure 67. Global Revenue Market Share of Vaginal Yeast Infections Drug by Application (2021–2032)
Figure 68. Global Vaginal Yeast Infections Drug Price (US$/Unit) by Application (2021–2032)
Figure 69. Vaginal Yeast Infections Drug Value Chain
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Table 1. Global Vaginal Yeast Infections Drug Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Vaginal Yeast Infections Drug Market Value by Disease Type (US$ Million), 2025 vs 2032
Table 3. Global Vaginal Yeast Infections Drug Market Value by Drug Class (US$ Million), 2025 vs 2032
Table 4. Global Vaginal Yeast Infections Drug Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global Vaginal Yeast Infections Drug Market Competitive Situation by Manufacturers in 2025
Table 6. Global Vaginal Yeast Infections Drug Sales (K Units) of Key Manufacturers (2021–2026)
Table 7. Global Vaginal Yeast Infections Drug Sales Market Share by Manufacturers (2021–2026)
Table 8. Global Vaginal Yeast Infections Drug Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global Vaginal Yeast Infections Drug Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market Vaginal Yeast Infections Drug Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of Vaginal Yeast Infections Drug, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of Vaginal Yeast Infections Drug, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of Vaginal Yeast Infections Drug, Product Types and Applications
Table 14. Global Key Manufacturers of Vaginal Yeast Infections Drug, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Vaginal Yeast Infections Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on Vaginal Yeast Infections Drug Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Vaginal Yeast Infections Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global Vaginal Yeast Infections Drug Sales by Region (K Units), 2021–2026
Table 20. Global Vaginal Yeast Infections Drug Sales Market Share by Region (2021–2026)
Table 21. Global Vaginal Yeast Infections Drug Sales by Region (K Units), 2027–2032
Table 22. Global Vaginal Yeast Infections Drug Sales Market Share by Region (2027–2032)
Table 23. Global Vaginal Yeast Infections Drug Revenue by Region (US$ Million), 2021–2026
Table 24. Global Vaginal Yeast Infections Drug Revenue Market Share by Region (2021–2026)
Table 25. Global Vaginal Yeast Infections Drug Revenue by Region (US$ Million), 2027–2032
Table 26. Global Vaginal Yeast Infections Drug Revenue Market Share by Region (2027–2032)
Table 27. North America Vaginal Yeast Infections Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America Vaginal Yeast Infections Drug Sales by Country (K Units), 2021–2026
Table 29. North America Vaginal Yeast Infections Drug Sales by Country (K Units), 2027–2032
Table 30. North America Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2021–2026
Table 31. North America Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2027–2032
Table 32. Europe Vaginal Yeast Infections Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe Vaginal Yeast Infections Drug Sales by Country (K Units), 2021–2026
Table 34. Europe Vaginal Yeast Infections Drug Sales by Country (K Units), 2027–2032
Table 35. Europe Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2021–2026
Table 36. Europe Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific Vaginal Yeast Infections Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific Vaginal Yeast Infections Drug Sales by Region (K Units), 2021–2026
Table 39. Asia Pacific Vaginal Yeast Infections Drug Sales by Region (K Units), 2027–2032
Table 40. Asia Pacific Vaginal Yeast Infections Drug Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific Vaginal Yeast Infections Drug Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America Vaginal Yeast Infections Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America Vaginal Yeast Infections Drug Sales by Country (K Units), 2021–2026
Table 44. Latin America Vaginal Yeast Infections Drug Sales by Country (K Units), 2027–2032
Table 45. Latin America Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa Vaginal Yeast Infections Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa Vaginal Yeast Infections Drug Sales by Country (K Units), 2021–2026
Table 49. Middle East and Africa Vaginal Yeast Infections Drug Sales by Country (K Units), 2027–2032
Table 50. Middle East and Africa Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa Vaginal Yeast Infections Drug Revenue by Country (US$ Million), 2027–2032
Table 52. Global Vaginal Yeast Infections Drug Sales (K Units) by Type (2021–2026)
Table 53. Global Vaginal Yeast Infections Drug Sales (K Units) by Type (2027–2032)
Table 54. Global Vaginal Yeast Infections Drug Sales Market Share by Type (2021–2026)
Table 55. Global Vaginal Yeast Infections Drug Sales Market Share by Type (2027–2032)
Table 56. Global Vaginal Yeast Infections Drug Revenue (US$ Million) by Type (2021–2026)
Table 57. Global Vaginal Yeast Infections Drug Revenue (US$ Million) by Type (2027–2032)
Table 58. Global Vaginal Yeast Infections Drug Revenue Market Share by Type (2021–2026)
Table 59. Global Vaginal Yeast Infections Drug Revenue Market Share by Type (2027–2032)
Table 60. Global Vaginal Yeast Infections Drug Price (US$/Unit) by Type (2021–2026)
Table 61. Global Vaginal Yeast Infections Drug Price (US$/Unit) by Type (2027–2032)
Table 62. Global Vaginal Yeast Infections Drug Sales (K Units) by Application (2021–2026)
Table 63. Global Vaginal Yeast Infections Drug Sales (K Units) by Application (2027–2032)
Table 64. Global Vaginal Yeast Infections Drug Sales Market Share by Application (2021–2026)
Table 65. Global Vaginal Yeast Infections Drug Sales Market Share by Application (2027–2032)
Table 66. Global Vaginal Yeast Infections Drug Revenue (US$ Million) by Application (2021–2026)
Table 67. Global Vaginal Yeast Infections Drug Revenue (US$ Million) by Application (2027–2032)
Table 68. Global Vaginal Yeast Infections Drug Revenue Market Share by Application (2021–2026)
Table 69. Global Vaginal Yeast Infections Drug Revenue Market Share by Application (2027–2032)
Table 70. Global Vaginal Yeast Infections Drug Price (US$/Unit) by Application (2021–2026)
Table 71. Global Vaginal Yeast Infections Drug Price (US$/Unit) by Application (2027–2032)
Table 72. Pfizer Company Information
Table 73. Pfizer Description and Business Overview
Table 74. Pfizer Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 75. Pfizer Vaginal Yeast Infections Drug Product
Table 76. Pfizer Recent Developments/Updates
Table 77. Bayer Company Information
Table 78. Bayer Description and Business Overview
Table 79. Bayer Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 80. Bayer Vaginal Yeast Infections Drug Product
Table 81. Bayer Recent Developments/Updates
Table 82. Sanofi Company Information
Table 83. Sanofi Description and Business Overview
Table 84. Sanofi Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 85. Sanofi Vaginal Yeast Infections Drug Product
Table 86. Sanofi Recent Developments/Updates
Table 87. Teva Pharmaceuticals Company Information
Table 88. Teva Pharmaceuticals Description and Business Overview
Table 89. Teva Pharmaceuticals Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 90. Teva Pharmaceuticals Vaginal Yeast Infections Drug Product
Table 91. Teva Pharmaceuticals Recent Developments/Updates
Table 92. Sandoz Company Information
Table 93. Sandoz Description and Business Overview
Table 94. Sandoz Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 95. Sandoz Vaginal Yeast Infections Drug Product
Table 96. Sandoz Recent Developments/Updates
Table 97. Prestige Consumer Healthcare Company Information
Table 98. Prestige Consumer Healthcare Description and Business Overview
Table 99. Prestige Consumer Healthcare Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 100. Prestige Consumer Healthcare Vaginal Yeast Infections Drug Product
Table 101. Prestige Consumer Healthcare Recent Developments/Updates
Table 102. Lupin Pharmaceuticals Company Information
Table 103. Lupin Pharmaceuticals Description and Business Overview
Table 104. Lupin Pharmaceuticals Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 105. Lupin Pharmaceuticals Vaginal Yeast Infections Drug Product
Table 106. Lupin Pharmaceuticals Recent Developments/Updates
Table 107. Bausch Health Company Information
Table 108. Bausch Health Description and Business Overview
Table 109. Bausch Health Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 110. Bausch Health Vaginal Yeast Infections Drug Product
Table 111. Bausch Health Recent Developments/Updates
Table 112. Globela Pharma Company Information
Table 113. Globela Pharma Description and Business Overview
Table 114. Globela Pharma Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 115. Globela Pharma Vaginal Yeast Infections Drug Product
Table 116. Globela Pharma Recent Developments/Updates
Table 117. Padagis Company Information
Table 118. Padagis Description and Business Overview
Table 119. Padagis Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 120. Padagis Vaginal Yeast Infections Drug Product
Table 121. Padagis Recent Developments/Updates
Table 122. Galderma Company Information
Table 123. Galderma Description and Business Overview
Table 124. Galderma Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 125. Galderma Vaginal Yeast Infections Drug Product
Table 126. Galderma Recent Developments/Updates
Table 127. Perrigo Company Information
Table 128. Perrigo Description and Business Overview
Table 129. Perrigo Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 130. Perrigo Vaginal Yeast Infections Drug Product
Table 131. Perrigo Recent Developments/Updates
Table 132. Johnson & Johnson Company Information
Table 133. Johnson & Johnson Description and Business Overview
Table 134. Johnson & Johnson Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 135. Johnson & Johnson Vaginal Yeast Infections Drug Product
Table 136. Johnson & Johnson Recent Developments/Updates
Table 137. Sinopharm Group Company Information
Table 138. Sinopharm Group Description and Business Overview
Table 139. Sinopharm Group Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 140. Sinopharm Group Vaginal Yeast Infections Drug Product
Table 141. Sinopharm Group Recent Developments/Updates
Table 142. Tongfang Pharmaceutical Company Information
Table 143. Tongfang Pharmaceutical Description and Business Overview
Table 144. Tongfang Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 145. Tongfang Pharmaceutical Vaginal Yeast Infections Drug Product
Table 146. Tongfang Pharmaceutical Recent Developments/Updates
Table 147. Lukang Pharmaceutical Company Information
Table 148. Lukang Pharmaceutical Description and Business Overview
Table 149. Lukang Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 150. Lukang Pharmaceutical Vaginal Yeast Infections Drug Product
Table 151. Lukang Pharmaceutical Recent Developments/Updates
Table 152. Kelun Pharmaceutical Company Information
Table 153. Kelun Pharmaceutical Description and Business Overview
Table 154. Kelun Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 155. Kelun Pharmaceutical Vaginal Yeast Infections Drug Product
Table 156. Kelun Pharmaceutical Recent Developments/Updates
Table 157. Shijiazhuang Pharmaceutical Group Company Information
Table 158. Shijiazhuang Pharmaceutical Group Description and Business Overview
Table 159. Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 160. Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Product
Table 161. Shijiazhuang Pharmaceutical Group Recent Developments/Updates
Table 162. Livzon Pharmaceutical Company Information
Table 163. Livzon Pharmaceutical Description and Business Overview
Table 164. Livzon Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 165. Livzon Pharmaceutical Vaginal Yeast Infections Drug Product
Table 166. Livzon Pharmaceutical Recent Developments/Updates
Table 167. Wuhan Haite Biopharmaceutical Company Information
Table 168. Wuhan Haite Biopharmaceutical Description and Business Overview
Table 169. Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 170. Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Product
Table 171. Wuhan Haite Biopharmaceutical Recent Developments/Updates
Table 172. Key Raw Materials Lists
Table 173. Raw Materials Key Suppliers Lists
Table 174. Vaginal Yeast Infections Drug Distributors List
Table 175. Vaginal Yeast Infections Drug Customers List
Table 176. Vaginal Yeast Infections Drug Market Trends
Table 177. Vaginal Yeast Infections Drug Market Drivers
Table 178. Vaginal Yeast Infections Drug Market Challenges
Table 179. Vaginal Yeast Infections Drug Market Restraints
Table 180. Research Programs/Design for This Report
Table 181. Key Data Information from Secondary Sources
Table 182. Key Data Information from Primary Sources
Table 183. Authors List of This Report
List of Figures
Figure 1. Product Picture of Vaginal Yeast Infections Drug
Figure 2. Global Vaginal Yeast Infections Drug Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Vaginal Yeast Infections Drug Market Share by Type: 2025 & 2032
Figure 4. Topical Drugs Product Picture
Figure 5. Oral Drugs Product Picture
Figure 6. Global Vaginal Yeast Infections Drug Market Value by Disease Type (US$ Million), 2021–2032
Figure 7. Global Vaginal Yeast Infections Drug Market Share by Disease Type: 2025 vs 2032
Figure 8. Uncomplicated VVC Product Picture
Figure 9. Complicated VVC Product Picture
Figure 10. Other Product Picture
Figure 11. Global Vaginal Yeast Infections Drug Market Value by Drug Class (US$ Million), 2021–2032
Figure 12. Global Vaginal Yeast Infections Drug Market Share by Drug Class: 2025 vs 2032
Figure 13. Azoles Product Picture
Figure 14. Polyenes Product Picture
Figure 15. Novel Oral Antifungals Product Picture
Figure 16. Other Product Picture
Figure 17. Global Vaginal Yeast Infections Drug Market Value by Application (US$ Million), 2021–2032
Figure 18. Global Vaginal Yeast Infections Drug Market Share by Application: 2025 & 2032
Figure 19. Hospital Pharmacies
Figure 20. Retail Pharmacies
Figure 21. Online
Figure 22. Global Vaginal Yeast Infections Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 23. Global Vaginal Yeast Infections Drug Market Size (US$ Million), 2021–2032
Figure 24. Global Vaginal Yeast Infections Drug Sales (K Units), 2021–2032
Figure 25. Global Vaginal Yeast Infections Drug Average Price (US$/Unit), 2021–2032
Figure 26. Vaginal Yeast Infections Drug Report Years Considered
Figure 27. Vaginal Yeast Infections Drug Sales Share by Manufacturers in 2025
Figure 28. Global Vaginal Yeast Infections Drug Revenue Share by Manufacturers in 2025
Figure 29. Top 5 and Top 10 Global Vaginal Yeast Infections Drug Players: Market Share by Revenue in Vaginal Yeast Infections Drug in 2025
Figure 30. Vaginal Yeast Infections Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 31. Global Vaginal Yeast Infections Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 32. North America Vaginal Yeast Infections Drug Sales Market Share by Country (2021–2032)
Figure 33. North America Vaginal Yeast Infections Drug Revenue Market Share by Country (2021–2032)
Figure 34. United States Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Canada Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Europe Vaginal Yeast Infections Drug Sales Market Share by Country (2021–2032)
Figure 37. Europe Vaginal Yeast Infections Drug Revenue Market Share by Country (2021–2032)
Figure 38. Germany Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. France Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. U.K. Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Italy Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Russia Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Asia Pacific Vaginal Yeast Infections Drug Sales Market Share by Region (2021–2032)
Figure 44. Asia Pacific Vaginal Yeast Infections Drug Revenue Market Share by Region (2021–2032)
Figure 45. China Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Japan Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. South Korea Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. India Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Australia Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. China Taiwan Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Southeast Asia Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Latin America Vaginal Yeast Infections Drug Sales Market Share by Country (2021–2032)
Figure 53. Latin America Vaginal Yeast Infections Drug Revenue Market Share by Country (2021–2032)
Figure 54. Mexico Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Brazil Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Argentina Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Colombia Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Middle East and Africa Vaginal Yeast Infections Drug Sales Market Share by Country (2021–2032)
Figure 59. Middle East and Africa Vaginal Yeast Infections Drug Revenue Market Share by Country (2021–2032)
Figure 60. Turkey Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. Saudi Arabia Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 62. UAE Vaginal Yeast Infections Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 63. Global Sales Market Share of Vaginal Yeast Infections Drug by Type (2021–2032)
Figure 64. Global Revenue Market Share of Vaginal Yeast Infections Drug by Type (2021–2032)
Figure 65. Global Vaginal Yeast Infections Drug Price (US$/Unit) by Type (2021–2032)
Figure 66. Global Sales Market Share of Vaginal Yeast Infections Drug by Application (2021–2032)
Figure 67. Global Revenue Market Share of Vaginal Yeast Infections Drug by Application (2021–2032)
Figure 68. Global Vaginal Yeast Infections Drug Price (US$/Unit) by Application (2021–2032)
Figure 69. Vaginal Yeast Infections Drug Value Chain
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Extruded Grade PETG Market Research Report 2026
Feb 24, 26
Global Particle Testing & Analysis Market Research Report 2026
Feb 24, 26
Global Plastic Lens for Automotive Lights Market Research Report 2026
Feb 24, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232